Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Expenses: 2014-2024

Historic Operating Expenses for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to $1.1 billion.

  • Ultragenyx Pharmaceutical's Operating Expenses rose 21.86% to $330.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 10.97%. This contributed to the annual value of $1.1 billion for FY2024, which is 9.24% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Operating Expenses of $1.1 billion as of FY2024, which was up 9.24% from $1.0 billion recorded in FY2023.
  • In the past 5 years, Ultragenyx Pharmaceutical's Operating Expenses ranged from a high of $1.1 billion in FY2024 and a low of $601.1 million during FY2020.
  • Its 3-year average for Operating Expenses is $1.0 billion, with a median of $1.0 billion in 2022.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Operating Expenses surged by 38.07% in 2022 and then declined by 0.87% in 2023.
  • Ultragenyx Pharmaceutical's Operating Expenses (Yearly) stood at $601.1 million in 2020, then increased by 21.96% to $733.1 million in 2021, then spiked by 38.07% to $1.0 billion in 2022, then dropped by 0.87% to $1.0 billion in 2023, then grew by 9.24% to $1.1 billion in 2024.